{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T23:05:29Z","timestamp":1789686329812,"version":"4.0.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":83,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Antiretroviral therapy (ART) suppresses HIV replication and partially restores immune function, but immune recovery is often incomplete. Interleukin-6 (IL-6) and Interleukin-10 (IL-10) reflect opposing sides of the immune response, pro-inflammatory and regulatory, respectively. They may provide insight into the degree of residual immune dysregulation in people living with HIV (PLHIV) on treatment. This study aims to determine serum IL-6 and IL-10 levels in PLHIV on ART compared to HIV-negative controls.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A comparative cross-sectional study was conducted at the HIV Care and Treatment Clinic of the University of Port Harcourt Teaching Hospital (UPTH), Nigeria. Eighty-one participants were enrolled: 63 were living with HIV (27 on short-term ART [less than six months], 36 on long-term ART [two years or more]), and 18 HIV-negative controls. Serum IL-6 and IL-10 were quantified by enzyme-linked immunosorbent assay (ELISA). Group differences were assessed using one-way analysis of variance (ANOVA), Tukey HSD post hoc tests, and independent samples t-tests. The influence of age and sex on cytokine levels was examined by analysis of covariance (ANCOVA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      IL-6 was 7.35\u2009\u00b1\u20090.17 pg\/ml in the short-term ART group, 6.38\u2009\u00b1\u20090.12 pg\/ml in the long-term ART group, and 5.65\u2009\u00b1\u20090.15 pg\/ml in controls. All three pairwise comparisons were statistically significant (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). IL-10 was 6.42\u2009\u00b1\u20090.15 pg\/ml, 6.21\u2009\u00b1\u20090.11 pg\/ml, and 5.81\u2009\u00b1\u20090.22 pg\/ml across the same groups respectively. Only the comparison between the short-term ART group and controls was significant for IL-10. Age and sex had no statistically significant effect on either cytokine.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>IL-6 declines with longer ART but remains elevated above control levels even after years of treatment, indicating persistent residual inflammation. Interleukin 10 is elevated in treated individuals compared with controls but does not track ART duration. These findings support the value of cytokine profiling as a supplementary tool for monitoring immune status in ART-treated PLHIV in a Nigerian clinical setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-026-13859-6","type":"journal-article","created":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T16:44:02Z","timestamp":1782578642000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Serum Interleukin-6 and Interleukin-10 levels in people living with HIV on short-term and long-term antiretroviral therapy: a comparative cross-sectional study with HIV-negative controls"],"prefix":"10.1186","volume":"26","author":[{"given":"Adekunle Ayomide","family":"Adegoke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chizaram","family":"Onyeaghala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abel Oluwaseun","family":"Olojede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olufemi G.","family":"Omitola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chijioke A.","family":"Nwauche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,27]]},"reference":[{"key":"13859_CR1","unstructured":"Swinkels HM, Nguyen AD, Samandari T, Gulick PG. HIV and AIDS. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026. [updated 2026 Jan 14; cited 2026 Jun 25]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK534860\/."},{"key":"13859_CR2","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2147\/hiv.s32321","volume":"4","author":"O Oguntibeju","year":"2012","unstructured":"Oguntibeju O. Quality of life of people living with HIV and AIDS and antiretroviral therapy. HIV AIDS (Auckl). 2012;4:117. https:\/\/doi.org\/10.2147\/hiv.s32321.","journal-title":"HIV AIDS (Auckl)"},{"key":"13859_CR3","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3390\/v11030200","volume":"11","author":"S Zicari","year":"2019","unstructured":"Zicari S, Sessa L, Cotugno N, et al. Immune activation, inflammation, and non-AIDS co-morbidities in HIV-infected patients under long-term ART. Viruses. 2019;11:200. https:\/\/doi.org\/10.3390\/v11030200.","journal-title":"Viruses"},{"key":"13859_CR4","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1093\/cid\/cir729","volume":"53","author":"HE Rawizza","year":"2011","unstructured":"Rawizza HE, Chaplin B, Meloni ST. Immunologic criteria are poor predictors of virologic outcome: implications for HIV treatment monitoring in resource-limited settings. Clin Infect Dis. 2011;53:1283\u201390. https:\/\/doi.org\/10.1093\/cid\/cir729.","journal-title":"Clin Infect Dis"},{"key":"13859_CR5","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1093\/infdis\/jiv123","volume":"212","author":"AH Borges","year":"2015","unstructured":"Borges AH, O\u2019Connor JL, Phillips AN, et al. Factors associated with plasma IL-6 levels during HIV infection. J Infect Dis. 2015;212:585\u201395. https:\/\/doi.org\/10.1093\/infdis\/jiv123.","journal-title":"J Infect Dis"},{"key":"13859_CR6","doi-asserted-by":"publisher","first-page":"e41222","DOI":"10.1097\/md.0000000000041222","volume":"104","author":"EI Obeagu","year":"2025","unstructured":"Obeagu EI. Influence of cytokines on the recovery trajectory of HIV patients on antiretroviral therapy: a review. Medicine. 2025;104:e41222. https:\/\/doi.org\/10.1097\/md.0000000000041222.","journal-title":"Medicine"},{"key":"13859_CR7","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1093\/infdis\/jiw173","volume":"214","author":"AH Borges","year":"2016","unstructured":"Borges AH, Losso MH, Raffanti SR, et al. Interleukin 6 is a stronger predictor of clinical events than high-sensitivity C-reactive protein or D-dimer during HIV infection. J Infect Dis. 2016;214:408\u201318. https:\/\/doi.org\/10.1093\/infdis\/jiw173.","journal-title":"J Infect Dis"},{"key":"13859_CR8","doi-asserted-by":"publisher","first-page":"e0155100","DOI":"10.1371\/journal.pone.0155100","volume":"11","author":"B Grund","year":"2016","unstructured":"Grund B, Baker JV, Deeks SG, et al. Relevance of interleukin-6 and D-dimer for serious non-AIDS morbidity and death among HIV-positive adults on suppressive antiretroviral therapy. PLoS ONE. 2016;11:e0155100. https:\/\/doi.org\/10.1371\/journal.pone.0155100.","journal-title":"PLoS ONE"},{"key":"13859_CR9","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/82_2010_96","volume":"350","author":"EB Wilson","year":"2011","unstructured":"Wilson EB, Brooks DG. The role of IL-10 in regulating immunity to persistent viral infections. Curr Top Microbiol Immunol. 2011;350:39\u201365. https:\/\/doi.org\/10.1007\/82_2010_96.","journal-title":"Curr Top Microbiol Immunol"},{"key":"13859_CR10","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1093\/cid\/ciad199","volume":"77","author":"NT Funderburg","year":"2023","unstructured":"Funderburg NT, Shive CL, Chen Z, et al. Interleukin 6 blockade with tocilizumab diminishes indices of inflammation that are linked to mortality in treated human immunodeficiency virus infection. Clin Infect Dis. 2023;77:272\u20139. https:\/\/doi.org\/10.1093\/cid\/ciad199.","journal-title":"Clin Infect Dis"},{"key":"13859_CR11","doi-asserted-by":"publisher","first-page":"ofaa099","DOI":"10.1093\/ofid\/ofaa099","volume":"7","author":"JR Castillo-Mancilla","year":"2020","unstructured":"Castillo-Mancilla JR, Brown TT, Palella FJ, et al. Partial normalization of biomarkers of inflammation and immune activation among virally suppressed men with HIV infection and high ART adherence. Open Forum Infect Dis. 2020;7:ofaa099. https:\/\/doi.org\/10.1093\/ofid\/ofaa099.","journal-title":"Open Forum Infect Dis"},{"key":"13859_CR12","doi-asserted-by":"publisher","first-page":"e0156163","DOI":"10.1371\/journal.pone.0156163","volume":"11","author":"RM de Medeiros","year":"2016","unstructured":"de Medeiros RM, Valverde-Villegas JM, Junqueira DM, et al. Rapid and slow progressors show increased IL-6 and IL-10 levels in the pre-AIDS stage of HIV infection. PLoS ONE. 2016;11:e0156163. https:\/\/doi.org\/10.1371\/journal.pone.0156163.","journal-title":"PLoS ONE"},{"key":"13859_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15761\/BRCP.1000235","volume":"10","author":"EI Obeagu","year":"2025","unstructured":"Obeagu EI. Cytokine dysregulation in HIV infection and its clinical implications. Biomed Res Clin Pract. 2025;10:1\u20138. https:\/\/doi.org\/10.15761\/BRCP.1000235.","journal-title":"Biomed Res Clin Pract"},{"key":"13859_CR14","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1093\/jac\/dkv036","volume":"70","author":"JP Bastard","year":"2015","unstructured":"Bastard JP, Fellahi S, Couffignal C, et al. Increased systemic immune activation and inflammatory profile of long-term HIV-infected ART-controlled patients is related to personal factors, but not to markers of HIV infection severity. J Antimicrob Chemother. 2015;70:1816\u201324. https:\/\/doi.org\/10.1093\/jac\/dkv036.","journal-title":"J Antimicrob Chemother"},{"key":"13859_CR15","doi-asserted-by":"publisher","first-page":"154839","DOI":"10.1016\/j.cyto.2019.154839","volume":"125","author":"V Bordoni","year":"2019","unstructured":"Bordoni V, Sacchi A, Casetti R, et al. Impact of ART on dynamics of growth factors and cytokines in primary HIV infection. Cytokine. 2019;125:154839. https:\/\/doi.org\/10.1016\/j.cyto.2019.154839.","journal-title":"Cytokine"},{"key":"13859_CR16","unstructured":"Kish, L. Survey Sampling (1st ed.). John Wiley & Sons, New York:1965. pp. 97"},{"key":"13859_CR17","doi-asserted-by":"publisher","first-page":"e0281243","DOI":"10.1371\/journal.pone.0281243","volume":"18","author":"AA Onovo","year":"2023","unstructured":"Onovo AA, Kalaiwo A, Obanubi C, et al. Estimating subnational HIV prevalence in Nigeria using small area estimation technique. PLoS ONE. 2023;18:e0281243. https:\/\/doi.org\/10.1371\/journal.pone.0281243.","journal-title":"PLoS ONE"},{"key":"13859_CR18","doi-asserted-by":"publisher","unstructured":"Isnard S, Royston L, Byrne T, Mehraj V, Elderwish S, McVety S, et al. Relevance of biomarkers indicating gut damage and microbial translocation in people living with HIV. Front Immunol. 2023;14:1173956. https:\/\/doi.org\/10.3389\/fimmu.2023.1173956.","DOI":"10.3389\/fimmu.2023.1173956"},{"key":"13859_CR19","doi-asserted-by":"publisher","first-page":"e0307003","DOI":"10.1371\/journal.pone.0307003","volume":"19","author":"D Kamori","year":"2024","unstructured":"Kamori D, Barabona G, Maokola W, et al. HIV viral suppression in the era of dolutegravir use: findings from a national survey in Tanzania. PLoS ONE. 2024;19:e0307003. https:\/\/doi.org\/10.1371\/journal.pone.0307003.","journal-title":"PLoS ONE"},{"key":"13859_CR20","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1038\/nm1511","volume":"12","author":"JM Brenchley","year":"2006","unstructured":"Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006;12:1365\u201371. https:\/\/doi.org\/10.1038\/nm1511.","journal-title":"Nat Med"},{"key":"13859_CR21","doi-asserted-by":"publisher","first-page":"822153","DOI":"10.3389\/fviro.2022.822153","volume":"2","author":"L Taramasso","year":"2023","unstructured":"Taramasso L, Labate L, Briano F, et al. CD4 + T lymphocyte recovery in the modern antiretroviral therapy era: toward a new threshold for defining immunological non-responders. Front Virol. 2023;2:822153. https:\/\/doi.org\/10.3389\/fviro.2022.822153.","journal-title":"Front Virol"},{"key":"13859_CR22","doi-asserted-by":"publisher","first-page":"e0240880","DOI":"10.1371\/journal.pone.0240880","volume":"15","author":"D Wolday","year":"2020","unstructured":"Wolday D, Legesse D, Kebede Y, Siraj DS, McBride JA, Striker R. Immune recovery in HIV-1 infected patients with sustained viral suppression under long-term antiretroviral therapy in Ethiopia. PLoS ONE. 2020;15:e0240880. https:\/\/doi.org\/10.1371\/journal.pone.0240880.","journal-title":"PLoS ONE"},{"key":"13859_CR23","doi-asserted-by":"publisher","first-page":"101471","DOI":"10.1016\/j.smim.2021.101471","volume":"51","author":"CW Cai","year":"2021","unstructured":"Cai CW, Sereti I. Residual immune dysfunction under antiretroviral therapy. Semin Immunol. 2021;51:101471. https:\/\/doi.org\/10.1016\/j.smim.2021.101471.","journal-title":"Semin Immunol"},{"key":"13859_CR24","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.immuni.2012.08.010","volume":"37","author":"E Eisele","year":"2012","unstructured":"Eisele E, Siliciano RF. Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity. 2012;37:377\u201388. https:\/\/doi.org\/10.1016\/j.immuni.2012.08.010.","journal-title":"Immunity"},{"key":"13859_CR25","doi-asserted-by":"publisher","unstructured":"Doyle T, Smith C, Vitiello P, Cambiano V, Johnson M, Owen A, et al. Plasma HIV-1 RNA detection below 50 copies\/ml and risk of virologic rebound in patients on potent antiretroviral therapy. Clin Infect Dis. 2012;54:724\u2013732. https:\/\/doi.org\/10.1093\/cid\/cir936.","DOI":"10.1093\/cid\/cir936"},{"key":"13859_CR26","doi-asserted-by":"publisher","unstructured":"Bruner KM, Wang Z, Simonetti FR, Bender AM, Kwon KJ, Sengupta S, et al. A quantitative approach for measuring the reservoir of latent HIV-1 proviruses. Nature. 2019;566:120\u201325. https:\/\/doi.org\/10.1038\/s41586-019-0898-8.","DOI":"10.1038\/s41586-019-0898-8"},{"key":"13859_CR27","doi-asserted-by":"publisher","unstructured":"Peluso MJ, Bacchetti P, Ryder AL, Hecht FM, Martin JN, Hunt PW, et al. Differential decay of intact and defective proviral DNA in HIV-1-infected individuals on suppressive antiretroviral therapy. JCI Insight. 2020;5:e132997. https:\/\/doi.org\/10.1172\/jci.insight.132997.","DOI":"10.1172\/jci.insight.132997"},{"key":"13859_CR28","doi-asserted-by":"publisher","unstructured":"Tincati C, Bono V, Cannizzo ES, Marchetti G. Primary HIV infection features colonic damage and neutrophil inflammation yet containment of microbial translocation. AIDS. 2024;38:623\u201332. https:\/\/doi.org\/10.1097\/QAD.0000000000003799.","DOI":"10.1097\/QAD.0000000000003799"},{"key":"13859_CR29","doi-asserted-by":"publisher","unstructured":"Crowell TA, Hatano H, Sinclair E, Henrich TJ, Hesselgesser J, Srinivasan A, et al. Progressive proximal-to-distal reduction in expression of the tight junction complex in colonic epithelium of virally-suppressed HIV+ individuals. PLoS Pathog. 2014;10:e1004198. https:\/\/doi.org\/10.1371\/journal.ppat.1004198.","DOI":"10.1371\/journal.ppat.1004198"},{"key":"13859_CR30","doi-asserted-by":"publisher","unstructured":"Lawn SD, Butera ST, Folks TM. Contribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infection. Clin Microbiol Rev. 2001;14:753\u201377. https:\/\/doi.org\/10.1128\/CMR.14.4.753-777.2001.","DOI":"10.1128\/CMR.14.4.753-777.2001"},{"key":"13859_CR31","doi-asserted-by":"publisher","unstructured":"Vujkovic-Cvijin I, Dunham RM, Iwai S, Maher MC, Albright RG, Broadhurst MJ, et al. Gut microbiota changes associated with epithelial barrier damage and systemic inflammation during antiretroviral therapy of chronic SIV infection. PLoS Pathog. 2021;17:e1009614. https:\/\/doi.org\/10.1371\/journal.ppat.1009614.","DOI":"10.1371\/journal.ppat.1009614"},{"key":"13859_CR32","doi-asserted-by":"publisher","unstructured":"Deeks SG, Tracy R, Douek DC. Systemic effects of inflammation on health during chronic HIV infection. Immunity. 2013;39:633\u201345. https:\/\/doi.org\/10.1016\/j.immuni.2013.10.001.","DOI":"10.1016\/j.immuni.2013.10.001"},{"key":"13859_CR33","doi-asserted-by":"publisher","unstructured":"Cao W, Mehraj V, Kaufmann DE, Li T, Routy JP. Elevation and persistence of CD8 T-cells in HIV infection: the Achilles heel in the ART era. J Int AIDS Soc. 2016;19:20697. https:\/\/doi.org\/10.7448\/IAS.19.1.20697.","DOI":"10.7448\/IAS.19.1.20697"},{"key":"13859_CR34","doi-asserted-by":"publisher","unstructured":"Ghneim K, Fournier M, Bhatt DL, Bhatt R, Massanella M, Ancuta P, et al. Examining chronic inflammation, immune metabolism, and T cell dysfunction in HIV infection. Viruses. 2024;16:219. https:\/\/doi.org\/10.3390\/v16020219.","DOI":"10.3390\/v16020219"},{"key":"13859_CR35","doi-asserted-by":"publisher","unstructured":"El-Far M, Kouassi P, Sylla M, Zhang Y, Fouda A, Fabre J, et al. Markers of T cell exhaustion and senescence and their relationship to plasma TGF-beta levels in treated HIV+ immune non-responders. Front Immunol. 2021;12:638023. https:\/\/doi.org\/10.3389\/fimmu.2021.638023.","DOI":"10.3389\/fimmu.2021.638023"},{"key":"13859_CR36","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1097\/qad.0000000000001149","volume":"30","author":"DC Hsu","year":"2016","unstructured":"Hsu DC, Ma YF, Hur S, et al. Plasma IL-6 levels are independently associated with atherosclerosis and mortality in HIV-infected individuals on suppressive antiretroviral therapy. AIDS. 2016;30:2065\u201374. https:\/\/doi.org\/10.1097\/qad.0000000000001149.","journal-title":"AIDS"},{"key":"13859_CR37","doi-asserted-by":"publisher","unstructured":"Kalayjian RC, Machekano RN, Rizk N, Robbins GK, Gandhi RT, Rodriguez BA, et al. Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy. J Infect Dis. 2010;201:1796\u20131805. https:\/\/doi.org\/10.1086\/652750.","DOI":"10.1086\/652750"},{"key":"13859_CR38","doi-asserted-by":"publisher","first-page":"1161067","DOI":"10.3389\/fimmu.2023.1161067","volume":"14","author":"V Carlini","year":"2023","unstructured":"Carlini V, Noonan DM, Abdalalem E, et al. The multifaceted nature of IL-10: regulation, role in immunological homeostasis and its relevance to cancer, COVID-19 and post-COVID conditions. Front Immunol. 2023;14:1161067. https:\/\/doi.org\/10.3389\/fimmu.2023.1161067.","journal-title":"Front Immunol"},{"key":"13859_CR39","doi-asserted-by":"publisher","unstructured":"Brockman MA, Kwon DS, Tighe DP, Pavlik DF, Rosato PC, Sela J, et al. IL-10 is up-regulated in multiple cell types during viremic HIV infection and reversibly inhibits virus-specific T cells. Blood. 2009;114:346\u201356. https:\/\/doi.org\/10.1182\/blood-2008-09-178160.","DOI":"10.1182\/blood-2008-09-178160"},{"key":"13859_CR40","doi-asserted-by":"publisher","unstructured":"Hyun JW, Lee JS, Kim YN, Kim SH. Emergence of a distinct HIV-specific IL-10-producing CD8+ T-cell subset with immunomodulatory functions during chronic HIV-1 infection. Immunology. 2013;140:346\u201356. https:\/\/doi.org\/10.1111\/imm.12141.","DOI":"10.1111\/imm.12141"},{"key":"13859_CR41","doi-asserted-by":"publisher","unstructured":"Migueles SA, Connors M. Success and failure of the cellular immune response against HIV-1. Nat Immunol. 2015;16:563\u201370. https:\/\/doi.org\/10.1038\/ni.3161.","DOI":"10.1038\/ni.3161"},{"key":"13859_CR42","doi-asserted-by":"publisher","unstructured":"Nasi M, De Biasi S, Gibellini L, Bianchini E, Pecorini S, Bacca V, et al. Ageing and inflammation in patients with HIV infection. Clin Exp Immunol. 2017;187:44\u201352. https:\/\/doi.org\/10.1111\/cei.12814.","DOI":"10.1111\/cei.12814"},{"key":"13859_CR43","doi-asserted-by":"publisher","unstructured":"Guaraldi G, Zona S, Menozzi M, Carli F, Dolci G, Santoro A, et al. Effect of antiretroviral therapy on the natural history of aging biomarkers in HIV-infected men. J Acquir Immune Defic Syndr. 2020;83:73\u201382. https:\/\/doi.org\/10.1097\/QAI.0000000000002215.","DOI":"10.1097\/QAI.0000000000002215"},{"key":"13859_CR44","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1093\/gerona\/glp198","volume":"65","author":"RP Stowe","year":"2010","unstructured":"Stowe RP, Peek MK, Cutchin MP, Goodwin JS. Plasma cytokine levels in a population-based study: relation to age and ethnicity. J Gerontol Biol Sci Med Sci. 2010;65:429\u201333. https:\/\/doi.org\/10.1093\/gerona\/glp198.","journal-title":"J Gerontol Biol Sci Med Sci"},{"key":"13859_CR45","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1177\/1753425917707026","volume":"23","author":"A Wegner","year":"2017","unstructured":"Wegner A, Benson S, Rebernik L, et al. Sex differences in the pro-inflammatory cytokine response to endotoxin unfold in vivo but not ex vivo in healthy humans. Innate Immun. 2017;23:432\u20139. https:\/\/doi.org\/10.1177\/1753425917707026.","journal-title":"Innate Immun"},{"key":"13859_CR46","doi-asserted-by":"publisher","first-page":"3861","DOI":"10.3390\/ijms21113861","volume":"21","author":"S Bernardi","year":"2020","unstructured":"Bernardi S, Toffoli B, Tonon F, et al. Sex differences in proatherogenic cytokine levels. Int J Mol Sci. 2020;21:3861. https:\/\/doi.org\/10.3390\/ijms21113861.","journal-title":"Int J Mol Sci"},{"key":"13859_CR47","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3390\/microorganisms11010052","volume":"11","author":"E Quiros-Roldan","year":"2023","unstructured":"Quiros-Roldan E, Pierobon E, Zanella I, et al. The impact of antiretroviral drugs on gut microbiota and the immune system: comparison between NRTI\/NNRTI- and INSTI-based regimens. Microorganisms. 2023;11:52. https:\/\/doi.org\/10.3390\/microorganisms11010052.","journal-title":"Microorganisms"},{"key":"13859_CR48","doi-asserted-by":"publisher","unstructured":"Serrano-Villar S, Cohen C, Baker JV, Haubrich R, Brunetta E, Hsue P, et al. Translating the observed differences in interleukin-6 levels between some antiretroviral regimens into potential long-term risk of serious non-AIDS events: a modelling study. Front Immunol. 2022;13:976564. https:\/\/doi.org\/10.3389\/fimmu.2022.976564.","DOI":"10.3389\/fimmu.2022.976564"},{"key":"13859_CR49","unstructured":"World Health Organization. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. WHO; 2021. Accessed March 2025. https:\/\/www.who.int\/publications\/i\/item\/9789240031593."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13859-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13859-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13859-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:38:05Z","timestamp":1789684685000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13859-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,27]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13859"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13859-6","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,27]]},"assertion":[{"value":"25 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was granted by the University of Port Harcourt Teaching Hospital Health Research Ethics Committee (NHREC\/UPTHHREC\/03\/2023). All procedures were conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants prior to enrolment.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1675"}}